The central question the Iranian team asked was deceptively simple: can a quantitative calcium score measured on a gated CT scan predict whether a PTMC procedure will succeed on the table, in real time, before the patient leaves the catheterization laboratory? For decades, cardiologists have relied on the Wilkins score, an echocardiographic grading system that scores four features of the mitral valve, leaflet mobility, leaflet thickening, calcification, and the state of the subvalvular apparatus, each on a scale from one to four. A combined score above eight generally warns of a difficult procedure and poorer outcomes. The Wilkins score has endured because it is cheap and uses equipment every cardiology unit already owns, but it is subjective, semi-quantitative, and depends heavily on the experience of the reader. CT, by contrast, offers an objective, reproducible number derived directly from the density of calcium deposits in the valve tissue.

The study enrolled thirty patients with severe rheumatic mitral stenosis who were scheduled for PTMC. Each participant underwent both a standard transthoracic echocardiographic assessment, from which the Wilkins score was calculated, and an electrocardiogram-gated CT scan of the heart, from which the researchers derived a mitral valve calcium score, abbreviated MVCS. The investigators then defined procedural success in clinically meaningful terms: either a post-procedure mitral valve area of at least 1.5 square centimeters, or at least a fifty percent increase in valve area from the baseline measurement, without the development of significant mitral regurgitation, meaning moderate-severe or severe leakage through the valve. This dual criterion matters because a balloon that splits the valve too aggressively can convert a stenotic valve into a leaking one, an outcome that is often worse than the disease it was meant to treat.

The headline result was that procedural success was achieved in eighteen of the thirty patients, a rate of sixty percent. When the researchers compared the patients in whom the procedure failed with those in whom it succeeded, several patterns emerged. Failed procedures were associated with numerically higher Wilkins scores, averaging 9.55 compared with 8.58 in the success group, a difference that approached but did not clearly cross the threshold of conventional statistical significance, with a p value of 0.05. More strikingly, patients with failed procedures had dramatically higher CT-derived calcium scores on average, 16.08 versus 0.76, and a far greater burden of significant post-procedural mitral regurgitation, affecting 41.7 percent of the failure group compared with none of the success group.

Yet the researchers were careful, and admirably so, about what these numbers do and do not prove. Because the CT-derived calcium measurements followed a zero-inflated distribution, meaning that many patients had no detectable valve calcium at all while a few had very high scores, the team performed an exploratory binary analysis comparing patients with detectable calcium against those without. In that analysis, the association between calcium burden and procedural failure was numerically apparent but statistically inconclusive, with a p value of 0.929 for the comparison of mean calcium scores. In other words, the raw averages looked compelling, but with only thirty patients, the study lacked the statistical power to confirm that the CT calcium score independently predicts outcome. This is a crucial nuance that separates responsible science from headline-grabbing overclaiming, and it is a nuance the authors themselves emphasize in their conclusions.

What the study did establish more firmly was the continued relevance of the Wilkins score. Using receiver operating characteristic analysis, the investigators found that the Wilkins score showed moderate discrimination for the immediate procedural outcome, with an area under the curve of 0.72 and a ninety-five percent confidence interval spanning 0.51 to 0.93. An AUC of 0.72 means that if you picked one patient who succeeded and one who failed at random, the Wilkins score would correctly rank the higher-risk patient about seventy-two percent of the time. That is useful but far from definitive, which is precisely why the search for complementary imaging markers continues. The confidence interval, stretching from barely better than chance to quite good, reflects the small sample size and underscores the need for larger validation cohorts.

The biological logic behind the calcium hypothesis is sound and worth understanding. Rheumatic mitral stenosis is fundamentally a disease of fusion, the commissures, or junctions, between the valve leaflets are glued together by inflammation and scarring following rheumatic fever. The balloon works by forcibly splitting these fused commissures. When the leaflets are pliable and the fusion is the dominant problem, the balloon splits cleanly and the valve opens. But when the leaflets are heavily calcified, the calcium deposits act like concrete within the valve structure, resisting the balloon and, worse, fracturing unpredictably. A crack through a calcium plate rather than along a commissural line can tear the leaflet itself, producing the abrupt, severe regurgitation that the study observed in the failed procedures. Calcium, in this sense, is not merely a marker of chronicity but a direct mechanical obstacle to the procedure’s mechanism of action.

This is where CT scoring offers a genuine conceptual advance over echocardiography. The Wilkins calcification grade asks a sonographer to eyeball the valve and assign a subjective number. A CT calcium score, by contrast, applies an objective attenuation threshold, typically around 130 Hounsfield units, the same standard used for coronary artery calcium scoring, and quantifies the actual volume or mass of calcified tissue. The measurement is reproducible across readers and centers, can be acquired during a single breath-hold, and increasingly comes free of charge when patients already undergo cardiac CT for other reasons, such as pre-procedural planning for left atrial appendage occlusion or AFib ablation. For patients in whom a CT scan is already planned, extracting a mitral valve calcium score adds no radiation, no cost, and no additional visit.

The clinical implications, if the findings are confirmed, could be significant for the global burden of rheumatic heart disease. Although rheumatic fever has become rare in high-income countries, it remains endemic across South Asia, sub-Saharan Africa, the Middle East, and parts of Latin America, where PTMC is often the only realistic treatment option given the scarcity of cardiac surgery capacity. A reliable pre-procedural predictor of failure would allow clinicians to triage patients more intelligently, reserving balloon commissurotomy for valves likely to respond and directing high-calcium valves toward surgical repair or replacement where feasible. It could also inform procedural technique itself, since operators might approach heavily calcified valves with smaller balloon sizes or staged dilations to reduce the risk of catastrophic leaflet tearing.

The authors of the study are appropriately measured in their conclusions, stating that CT calcium scoring may serve as a complementary anatomical marker in selected patients but that larger studies are needed to define its incremental value over the Wilkins score. That framing is exactly right for a thirty-patient exploratory investigation. What the study provides is a proof of concept and a methodological template: a rigorous definition of success, a quantitative imaging biomarker, and an honest statistical treatment of a skewed data distribution. If subsequent multicenter trials with hundreds of patients confirm that a threshold CT calcium score reliably identifies valves destined to fail balloon dilation, the mitral valve calcium score could join the Wilkins score as a standard element of the pre-PTMC workup, giving cardiologists in resource-limited settings a sharper tool for deciding which valves can be saved by a balloon and which require something more. For now, the message for patients and clinicians alike is one of cautious optimism: the technology to see inside a stiffened valve in exquisite detail already exists, and the evidence that it can predict procedural fate is accumulating, one carefully designed study at a time.

Subject of Research: CT-based mitral valve calcium scoring as a predictor of immediate outcomes after percutaneous transvenous mitral commissurotomy in rheumatic mitral stenosis

Article Title: CT mitral valve calcium score and immediate outcomes after percutaneous transvenous mitral commissurotomy

Article References: Eini, P., Jolfayi, A. G., Firouzi, A., Rafiee, F., Ranjbar, B., Kaviani, R., Parsaee, M., Alemzadeh-Ansari, M. J., Bakhshandeh, H., Maleki, M., & Houshmand, G. (2026). CT mitral valve calcium score and immediate outcomes after percutaneous transvenous mitral commissurotomy. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02843-w

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02843-w

Keywords: rheumatic mitral stenosis, PTMC, mitral valve calcium score, computed tomography, Wilkins score, echocardiography, mitral regurgitation, balloon commissurotomy, cardiac imaging, procedural outcomes, valvular heart disease, BMC Medical Imaging